Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – ,
The Italian based firm produces the only 100% natural canned Italian Prosecco and Prosecco Cocktails on the market. The company was named Double Gold and Gold Awards winner for every product in the line-up, awards that recognize outstanding design and quality. With their colorful quality brand designed for the joyful Bohemian consumer, their products are available in the US in over 250 locations in two states through different distribution contracts and online in 48 states. The firm growth ambition is to expand geographically on both coasts in the US, targeting to have 30,000 stores with distribution over the next 3 years and reach USD 24.4 million revenue in 2026. Sparkling wine consumption grew 28% by volume in 2021, while prosecco has replaced champagne as the world’s favorite sparkling wine. The firm partners with innovative brand developers who served Red Bull and Coca Cola and seeks to raise USD 1 million via convertible notes in its current round.
The company is building a tech-enabled omnichannel Chinese marketplace for European personal care and cosmetic products. It currently features Italian skincare and makeup brands DEBORAH, DERMOLAB, deBBY, SPECCHIASOL, and BIO ETYC Organic Skincare. In phase 1 the firm focuses on cross-border e-commerce, while marketing in China. After one year, the firm will commence phase 2, regular import and B2B offline distribution channels, targeting 60 Chinese cities by 2027 with bulk product strategy (such as in hair salons) and own-branded New Cosmetics Collection Stores, among others. Revenue is projected to grow from GBP 5M in 2023 to GBP 123 M in 2027. Featured brands are well established outside China and the management team has extensive experience in global healthcare MNCs, government relationships, sales and marketing of luxury goods, and IT. The Chinese health & beauty market is the world’s largest, fastest growing, and most accessible one, while being highly fragmented. The start-up raises GBP 10 M within 2022.
Asia: South Korea
The equipment developed by the Korean company will help overcome the process limits in the next generation of ultra-precision semiconductor device manufacturing / OLED display device manufacturing. The company's particle monitoring equipment can conduct real-time monitoring on nano-level particles (5-1000 nm). The performance is superior to the off-line monitoring products of KLA, Nanometrics, TSI, Aerodyne and other companies. The company's real-time gas monitoring products have high-speed, trace and high-resolution material analysis capability, strong anti-pollution performance, and can be monitored for a long time, which meets the engineering analysis performance requirements. The performance is superior to products of Inficon, MKS, AMETEK, Hiden Analytical and other companies. The company has a number of invention patents and many are being applied for. At present, it has become a supplier of leading enterprises such as Hynix and LG. It seeks a partial or full share sale of USD 37.4 million - 44.9 million.
The Japanese company uses genome editing technology to extract functional proteins from farmed chickens and provide them as pharmaceutical raw materials to antibody, vaccine and other pharmaceutical companies. The CTO and CSO are the active professor and associate professor of the University of Tokushima respectively. The company completed A-round financing of USD 6.2 million in 2020 and plans to launch B-round financing of USD 10 million in the near future. It hopes to establish cooperative relations with relevant Chinese enterprises and obtain Chinese investment.
The Japanese company is mainly engaged in R&D of medicines for autoimmune disorders and is also preparing to carry out R&D of cancer medicines related to harmonic T cells. At present, one of the two medicines in the pipeline has entered Phase II clinical trial. The company was restructured in 2018 and registered in Taiwan. Its total investment exceeds USD 33 million. It seeks pre-IPO financing of USD 12 million (USD 5 million has been injected), and then plans to be listed in Taiwan in 2023.
Japanese new human absorbable painless micro needle company seeks C-round financing of USD 7.46 million - 11.18 million.
The Japanese company is mainly engaged in R&D and production of medical products with optical and electrical technologies. The main products are painless needles with laser processing technology, which can be used in skincare and beauty, medical anesthesia, preventive needles, and other fields. The company completed Round B+ financing at the end of 2020, with overall B-round financing of USD 5.29 million (JPY 710 million). It seeks Round C financing of USD 7.46 million - 11.18 million (JPY 1 billion - 1.5 billion) and plans to complete the IPO by the end of 2023.
The Japanese company focuses on the development of intelligent wearable devices. Its non-intrusive blood glucose monitoring technology can avoid the harm to the body caused by the traditional blood glucose detection method while achieving the same detection effect as the traditional detection method. The core team members come from famous companies such as Sony, Toshiba, Dentsu and Toyota Tsusho Systems, and have rich experience in enterprise management and software and hardware development of electronic products. Since its establishment, the company has received USD 10 million from Taisho Pharmaceutical Group, Tomita and Alfresa Holdings. Now the company seeks financing.
The Japanese company mainly focuses on the development of new medicines for lifestyle diseases such as diabetes, hypertension, and hyperlipidemia. It currently has 7 product pipelines and three products of it have entered the Phase II clinical trial. The company is jointly funded by Innovation Network Corporation of Japan, Takeda and Medipal. Now it seeks financing.
The Japanese company is mainly engaged in the development of polymer microsphere technology, which can effectively improve the safety and effectiveness of proteins for cancer treatment. The technologies of protein packaging, protection and release independently developed by the company have applied for exclusive patents. The company has established cooperation with many well-known national and international pharmaceutical enterprises such as Bristol Myers Squibb, Ono Pharmaceutical Co., Merck, Daiichi-Sankyo, GSK and AstraZeneca to jointly promote project research and development ("R&D") and clinical trials. It now seeks financing.
The Japanese company is an intelligent wearable device technology supplier, which can provide detection solutions for blood pressure, heartbeat, body temperature, blood oxygen and other physical characteristics. The non-interventional blood glucose detection developed by the company can use the spectrometer to measure the blood glucose level of users in a non-invasive manner. At present, the company has obtained USD 10 million financing from Taisho Pharmaceutical Group and Alfresa Holdings Corporation. Now it seeks financing.
The Japanese company's main products include a hybrid battery system, which is compatible with lithium batteries, lead batteries, nickel-metal hydride batteries, etc., and lithium batteries with ultra-high power charge and dischagre. At the same time, it is also developing lithium batteries with ultra-high energy density and high-capacity anode materials. The company's products can be widely used in power storage, power generation systems, industrial batteries, decentralized batteries, electric vehicles and other fields. Since 2014, the total financing scale of the company has been nearly USD 14.9 million (JPY 2 billion). Investors include industrial giants such as Kansai Electric Power and Mitsubishi Materials. The company now seeks financing.
The Japanese company has exclusively developed single-cell genome analysis technology, which is the only effective technology that can obtain the complete genome sequence of microorganisms at present and can be used to serve the leading compound discovery, compound structure optimization, target gene research and other fields involved in the clinical development of pharmaceutical enterprises. The company has 19 employees. The four core founding team members come from well-known universities such as the University of Tokyo, Tokyo University of Agriculture and Technology and Kobe University, and have work experience in international pharmaceutical companies, scientific research institutions, the Boston Consulting Group and other institutions. In 2020, the company obtained B-round financing of USD 5.43 million (JPY 730 million), seeking C-round financing to expand to the Chinese market through technology licencing.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us